Oura’s indefinite postponement of its planned late-September 2026 Nasdaq IPO, which targeted a $15.6 billion valuation and up to $2.2 billion in proceeds at a $40–$44 share range, underpins the 95.7% market-implied odds of no listing before January 2027. The company cited IPO-market uncertainty despite strong initial demand and cornerstones from firms such as Dragoneer and Eli Lilly, electing to wait given its profitability and expected 90% revenue growth for fiscal 2026. With a private valuation near $11 billion from the prior Series E and continued subscriber expansion to roughly six million paid members, Oura retains flexibility on timing. A clearer path to an offering would require sustained improvement in equity-market sentiment or a fresh SEC filing that accelerates roadshow activity before year-end.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật1H6H1D7D30DALL
View resolved

Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp